Why Sharps Technology (STSS) Stock Is Skyrocketing
Why Sharps Technology (STSS) Stock Is Skyrocketing
Sharps Technology Inc (NASDAQ:STSS) shares are trading higher by 39.8% to $0.63 during Thursday's session after the company signed a 5-year $200 million syringe sales agreement with Nephron Pharmaceuticals.
夏普斯科技公司（納斯達克股票代碼：STSS）在週四的交易中股價上漲39.8％，至0.63美元，此前該公司與耐弗龍製藥簽署了爲期5年的2億美元注射器銷售協議。
The company says the deal complements Sharps Technology's acquisition of InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. The facility will be North America's only dedicated COC prefillable syringe manufacturing plant, featuring advanced production capabilities.
該公司表示，該交易補充了夏普斯科技收購位於南卡羅來納州西哥倫比亞的InjecteZ特種注射器製造資產。該工廠將是北美唯一的專用 COC 預充注射器製造工廠，具有先進的生產能力。
Product delivery is set to start in late second-quarter 2025, with expected revenue of about $37 million in the first year.
產品交付定於2025年第二季度末開始，預計第一年收入約爲3700萬美元。
How To Buy STSS Stock
如何購買STSS股票
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了前往經紀平台購買股票的股票（或部分股票）外，您還可以通過購買本身持有股票的交易所交易基金（ETF）來獲得股票，或者將自己分配到401（k）中尋求收購共同基金或其他工具股票的策略。
For example, in Sharps Technology's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，就夏普科技而言，它屬於醫療保健領域。ETF可能會持有許多有助於追蹤該行業的流動性和大型公司的股票，從而使投資者能夠了解該細分市場的趨勢。
According to data from Benzinga Pro, STSS has a 52-week high of $1.05 and a 52-week low of $0.17.
根據Benzinga Pro的數據，STSS的52周高點爲1.05美元，52周低點爲0.17美元。
譯文內容由第三人軟體翻譯。